Literature DB >> 16697815

An analysis of the natural history of Peyronie's disease.

John P Mulhall1, Jonathan Schiff, Patricia Guhring.   

Abstract

PURPOSE: Little information exists on the natural history of PD. We defined the course of PD in a group of men with this condition who received no treatment.
MATERIALS AND METHODS: The study population comprised patients with PD who presented within 6 months of disease onset, had no medical treatment and were followed until at least 12 months after disease onset. At baseline and followup penile abnormality was determined following intracavernous injection and by measurement at maximum penile rigidity.
RESULTS: A total of 246 patients met inclusion criteria. At presentation mean age +/- SD was 52 +/- 22 years and the duration of PD was 3.5 +/- 1.5 months. At baseline in men with documented curvature 72% had dorsal, 17% had ventral and 11% had lateral curvature. Mean curvature at baseline was 42 +/- 22 degrees. Mean stretched flaccid penile length was 12.2 cm. The mean duration of PD at the followup assessment was 18 +/- 7 months. At followup stretched flaccid length had decreased to 11.4 cm (p = 0.035). Of the patients 32% complained of some degree of erectile dysfunction at baseline. All patients who reported penile pain had improvement and 89% reported complete resolution at followup. Of men with curvature 12% had improved, 40% remained stable and 48% had worsened at followup. In those in whom curvature improved the mean change was 15 degrees, while in those in whom curvature worsened the mean change was 22 degrees.
CONCLUSIONS: To our knowledge this is the largest study to explore the natural history of PD. A minority of men experienced improvement in penile abnormality, while penile length decreased during the 1-year followup. This information will permit clinicians to provide patients with realistic expectations at presentation for the evaluation of PD.

Entities:  

Mesh:

Year:  2006        PMID: 16697815     DOI: 10.1016/S0022-5347(06)00270-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  72 in total

1.  PEYRONIE'S DISEASE: A REVIEW OF ETIOLOGY, DIAGNOSIS, AND MANAGEMENT.

Authors:  Aylin N Bilgutay; Alexander W Pastuszak
Journal:  Curr Sex Health Rep       Date:  2015-06-01

Review 2.  [Current therapeutic options for Peyronie's disease].

Authors:  A Hauptmann; T Diemer; W Weidner
Journal:  Urologe A       Date:  2013-10       Impact factor: 0.639

Review 3.  Treatment of Peyronie's disease: 2012 update.

Authors:  Ege Can Serefoglu; Wayne J G Hellstrom
Journal:  Curr Urol Rep       Date:  2011-12       Impact factor: 3.092

4.  [Peyronie's disease: diagnostics and therapy].

Authors:  A Hauptmann; T Diemer; W Weidner
Journal:  Urologe A       Date:  2011-05       Impact factor: 0.639

Review 5.  [Conservative therapy of Peyronie's disease - update 2015].

Authors:  G Hatzichristodoulou
Journal:  Urologe A       Date:  2015-05       Impact factor: 0.639

6.  Options for the Medical Treatment of Peyronie's Disease.

Authors:  Laurence A Levine; Sanford J Siegel
Journal:  Rev Urol       Date:  2014

Review 7.  Strategies for penile prosthesis placement in Peyronie's disease and corporal fibrosis.

Authors:  Faysal A Yafi; Premsant Sangkum; Ian Ross McCaslin; Wayne J G Hellstrom
Journal:  Curr Urol Rep       Date:  2015-04       Impact factor: 3.092

8.  Collagenase Clostridium Histolyticum for the Treatment of Peyronie's Disease: A 'Real World' Clinical Perspective.

Authors:  James Anaissie; Wayne J G Hellstrom; Faysal A Yafi
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

9.  2018 Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature.

Authors:  Anthony J Bella; Jay C Lee; Ethan D Grober; Serge Carrier; Francois Benard; Gerald B Brock
Journal:  Can Urol Assoc J       Date:  2018-02-22       Impact factor: 1.862

10.  Intralesional hyaluronic acid: an innovative treatment for Peyronie's disease.

Authors:  Romano Gennaro; Davide Barletta; Gianni Paulis
Journal:  Int Urol Nephrol       Date:  2015-08-11       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.